These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 2875919

  • 1. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R, Kaesemann H, Caffier H.
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [Abstract] [Full Text] [Related]

  • 2. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R, Hafter R, Schmid L, Babic R, Ulm K, Gössner W, Graeff H.
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of different serum tumor markers in gynecological malignancies.
    Paulick R, Caffier H, Horner G, Lang K, Filbry E.
    Cancer Detect Prev; 1985 Jan; 8(1-2):115-20. PubMed ID: 4064031
    [Abstract] [Full Text] [Related]

  • 4. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
    Paulick R, Caffier H, Paulick M.
    Cancer Detect Prev; 1987 Jan; 10(3-4):197-203. PubMed ID: 3568016
    [Abstract] [Full Text] [Related]

  • 5. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M.
    Wien Klin Wochenschr; 1986 May 16; 98(10):319-25. PubMed ID: 3460273
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A, Caciagli M, Zampieri F, Ciampalini G, Carpi A, Spisni R, Colizzi C.
    Cancer Detect Prev; 1995 May 16; 19(2):183-95. PubMed ID: 7750106
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum tumor markers in metastatic breast cancer and course of disease.
    Caffier H, Brandau H.
    Cancer Detect Prev; 1983 May 16; 6(4-5):451-7. PubMed ID: 6197167
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
    Negishi Y, Furuno K, Sano Y, Hirata T, Utsunomiya A, Nakajima H, Okabe K, Shimizu K, Akiya K, Fujiwara Y.
    Gan No Rinsho; 1985 May 16; 31(6 Suppl):655-63. PubMed ID: 2993692
    [Abstract] [Full Text] [Related]

  • 16. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G, Zippel HH, Würz H.
    Geburtshilfe Frauenheilkd; 1985 Apr 16; 45(4):205-12. PubMed ID: 2408962
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Tumor markers in gynecologic diseases].
    Geyer H, Kleine W.
    Geburtshilfe Frauenheilkd; 1987 Mar 16; 47(3):168-72. PubMed ID: 3472991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.